Application of the ApcMin/+ mouse model for studying inflammation-associated intestinal tumor

Biomedicine and Pharmacotherapy

Volumn 71, Issue , 2015, Pages 216-221

  Wang, Lu ^a   Zhang, Qingzhu ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Apc; Inflammation; Intestinal adenoma; Min; Mouse

Indexed keywords

7 CHLORO 3 IMINO 5 METHYL 2 AZABICYCLO[4.1.0]HEPTANE; ACETYLSALICYLIC ACID; APC PROTEIN; CELECOXIB; CURCUMIN; MESALAZINE; QUERCETIN; RESVERATROL; SILIBININ; SULINDAC; ANTINEOPLASTIC AGENT;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; CANCER STAGING; COLON CARCINOGENESIS; ENTERITIS; ENVIRONMENTAL FACTOR; GENE CONTROL; INTESTINE FLORA; INTESTINE TUMOR; LIFESTYLE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; COLON POLYPOSIS; DISEASE MODEL; GENETICS; INFLAMMATION; INTESTINAL NEOPLASMS; MICROBIOLOGY; MOUSE; PATHOLOGY;

ADENOMATOUS POLYPOSIS COLI; ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; INFLAMMATION; INTESTINAL NEOPLASMS; LIFE STYLE; MICE;

EID: 84928941368     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2015.02.023     Document Type: Review

References (70)

1. Huang E.H., Park J.C., Appelman H., Weinberg A.D., Banerjee M., Logsdon C.D., et al. Induction of inflammatory bowel disease accelerates adenoma formation in Min+/- mice. Surgery 2006, 139:782-788.
2. Tanaka T. Development of an inflammation-associated colorectal cancer model and its application for research on carcinogenesis and chemoprevention. Int J Inflam 2012, 2012:658786.
3. McCart A.E., Vickaryous N.K., Silver A. Apc mice: models, modifiers and mutants. Pathol Res Pract 2008, 204:479-490.
4. Ishikawa T.O., Tamai Y., Li Q., Oshima M., Taketo M.M. Requirement for tumor suppressor Apc in the morphogenesis of anterior and ventral mouse embryo. Dev Biol 2003, 253:230-246.
5. Moser A.R., Pitot H.C., Dove W.F. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990, 247:322-324.
6. Halberg R.B., Katzung D.S., Hoff P.D., Moser A.R., Cole C.E., Lubet R.A., et al. Tumorigenesis in the multiple intestinal neoplasia mouse: redundancy of negative regulators and specificity of modifiers. Proc Natl Acad Sci U S A 2000, 97:3461-3466.
7. Half E., Bercovich D., Rozen P. Familial adenomatous polyposis. Orphanet J Rare Dis 2009, 4:22.
8. Dhir M., Montgomery E.A., Glöckner S.C., Schuebel K.E., Hooker C.M., Herman J.G., et al. Epigenetic regulation of WNT signaling pathway genes in inflammatory bowel disease (IBD) associated neoplasia. J Gastrointest Surg 2008, 12:1745-1753.
9. Sparks A.B., Morin P.J., Vogelstein B., Kinzler K.W. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 1998, 58:1130-1134.
10. Min/+ mice increases intestinal tumor burden. PLoS ONE 2010, 5:e9070.
11. Zhu W., Fang C., Gramatikoff K., Niemeyer C.C., Smith J.W. Proteins and an inflammatory network expressed in colon tumors. J Proteome Res 2011, 10:2129-2139.
12. Min/+ mouse model of colon cancer cachexia. Biochim Biophys Acta 2011, 1812:1601-1606.
13. Landskron G., De la Fuente M., Thuwajit P., Thuwajit C., Hermoso M.A. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res 2014, 2014:149185.
14. Chae W.J., Gibson T.F., Zelterman D., Hao L., Henegariu O., Bothwell A.L. Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis. Proc Natl Acad Sci U S A 2010, 107:5540-5544.
15. Min/+ mice. Biochem Biophys Res Commun 2011, 414:31-36.
16. Seno H., Oshima M., Ishikawa T.O., Oshima H., Takaku K., Chiba T., et al. Cyclooxygenase 2- and prostaglandin E2 receptor EP2-dependent angiogenesis in Apc716 mouse intestinal polyps. Cancer Res 2002, 62:506-511.
17. McClellan J.L., Davis J.M., Steiner J.L., Enos R.T., Jung S.H., Carson J.A., et al. Linking tumor-associated macrophages, inflammation, and intestinal tumorigenesis: role of MCP-1. Am J Physiol Gastrointest Liver Physiol 2012, 303:G1087-G1095.
18. Wilson J.M., Coletta P.L., Cuthbert R.J., Scott N., MacLennan K., Hawcroft G., et al. Macrophage migration inhibitory factor promotes intestinal tumorigenesis. Gastroenterology 2005, 129:1485-1503.
19. Min/+ mice. Nat Med 2010, 16:665-670.
20. Wang L., Wang Y., Song Z., Chu J., Qu X. Deficiency of interferon-gamma or its receptor promotes colorectal cancer development. J Interferon Cytokine Res 2014, 10.1089/jir.2014.0132.
21. Shaked H., Hofseth L.J., Chumanevich A., Chumanevich A.A., Wang J., Wang Y., et al. Chronic epithelial NF-κB activation accelerates APC loss and intestinal tumor initiation through iNOS up-regulation. Proc Natl Acad Sci U S A 2012, 109:14007-14012.
22. Asfaha S., Dubeykovskiy A.N., Tomita H., Yang X., Stokes S., Shibata W., et al. Mice that express human interleukin-8 have increased mobilization of immature myeloid cells, which exacerbates inflammation and accelerates colon carcinogenesis. Gastroenterology 2013, 144:155-166.
23. Min/+ mice. Am J Physiol Regul Integr Comp Physiol 2008, 294:R393-R401.
24. Xiao H., Yin W., Khan M.A., Gulen M.F., Zhou H., Sham H.P., et al. Loss of single immunoglobulin interlukin-1 receptor-related molecule leads to enhanced colonic polyposis in Apcmin mice. Gastroenterology 2010, 139:574-585.
25. Sakai H., Yamada Y., Shimizu M., Saito K., Moriwaki H., Hara A. Genetic ablation of Tnfalpha demonstrates no detectable suppressive effect on inflammation-related mouse colontumorigenesis. Chem Biol Interact 2010, 184:423-430.
26. Rizzo A., Pallone F., Monteleone G., Fantini M.C. Intestinal inflammation and colorectal cancer: a double-edged sword?. World J Gastroenterol 2011, 17:3092-3100.
27. Edwards P., Cendan J.C., Topping D.B., Moldawer L.L., MacKay S., et al. Tumor cell nitric oxide inhibits cell growth in vitro, but stimulates tumorigenesis and experimental lung metastasis in vivo. J Surg Res 1996, 63:49-52.
28. Min/+ mouse. Gastroenterology 2001, 121:889-899.
29. Tjandra S.S., Hsu C., Goh Y.I., Gurung A., Poon R., Nadesan P., et al. IFN-β signaling positively regulates tumorigenesis in aggressive fibromatosis, potentially by modulating mesenchymal progenitors. Cancer Res 2007, 67:7124-7131.
30. Garcia-Lora A., Algarra I., Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 2003, 195:346-355.
31. Swann J.B., Smyth M.J. Immune surveillance of tumors. J Clin Invest 2007, 117:1137-1146.
32. Song Y., Zhu X. Current progress of the mechanism of tumor immune escape. Mod Oncol 2011, 19:1230-1234.
33. Nagamine C.M., Sohn J.J., Rickman B.H., Rogers A.B., Fox J.G., Schauer D.B. Helicobacter hepaticus infection promotes colon tumorigenesis in the BALB/c-Rag2(-/-)ApcMin/+ mouse. Infect Immun 2008, 76:2758-2766.
34. Bassing C.H., Swat W., Alt F.W. The mechanism and regulation of chromosomal V(D)J recombination. Cell 2002, 109(Suppl.):S45-S55.
35. Mombaerts P., Iacomini J., Johnson R.S., Herrup K., Tonegawa S., Papaioannou V.E. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 1992, 68:869-877.
36. Min/+ mice. Int J Oncol 2012, 40:243-250.
37. Kettunen H.L., Kettunen A.S., Rautonen N.E. Intestinal immune responses in wild-type and ApcMin/+ mouse, a model for colon cancer. Cancer Res 2003, 63:5136-5142.
38. Stransky B., de Souza S.J. Modeling tumor evolutionary dynamics. Front Physiol 2012, 3:480.
39. Ji D., Cui J. Relationship between the initiation, development and therapy of tumor and inflammation. Chin J New Drugs 2010, 19:1551-1555.
40. Baker P.I., Love D.R., Ferguson L.R. Role of gut microbiota in Crohn's disease. Expert Rev Gastroenterol Hepatol 2009, 3:535-546.
41. Erickson A.R., Cantarel B.L., Lamendella R., Darzi Y., Mongodin E.F., Pan C., et al. Integrated metagenomics/metaproteomics reveals human host-microbiota signatures of Crohn's disease. PLoS ONE 2012, 7:e49138.
42. Min/+ mouse. Infect Immun 2008, 76:2758-2766.
43. Nagamine C.M., Rogers A.B., Fox J.G., Schauer D.B. Helicobacter hepaticus promotes azoxymethane-initiated colon tumorigenesis in BALB/c-IL10-deficient mice. Int J Cancer 2008, 122:832-838.
44. Yang L., Pei Z. Bacteria, inflammation, and colon cancer. World J Gastroenterol 2006, 12:6741-6746.
45. Min/+ mice. Carcinogenesis 2012, 33:1231-1238.
46. Min/+ mice. J Infect Dis 2001, 184:227-230.
47. Rao V.P., Poutahidis T., Ge Z., Nambiar P.R., Boussahmain C., Wang Y.Y., et al. Innate immune inflammatory response against enteric bacteria Helicobacter hepaticus induces mammary adenocarcinoma in mice. Cancer Res 2006, 66:7395-7400.
48. Min/+ model of intestinal carcinogenesis. Artif Cells Nanomed Biotechnol 2014, 25:1-11.
49. Lizarraga D., Vinardell M.P., Noé V., van Delft J.H., Alcarraz-Vizán G., van Breda S.G., et al. A lyophilized red grape pomace containing proanthocyanidin-rich dietary fiber induces genetic and metabolic alterations in colon mucosa of female C57BL/6J mice. J Nutr 2011, 141:1597-1604.
50. Forte A., De Sanctis R., Leonetti G., Manfredelli S., Urbano V., Bezzi M. Dietary chemoprevention of colorectal cancer. Ann Ital Chir 2008, 79:261-267.
51. Min/+ mice: relation to cell cycle and immuneresponse. Carcinogenesis 2013, 34:1881-1888.
52. Kim D.J., Shin D.H., Ahn B., Kang J.S., Nam K.T., Park C.B., et al. Chemoprevention of colon cancer by Korean food plant components. Mutat Res 2003, 523-524:99-107.
53. Min/+ mice. Cancer Prev Res (Phila) 2009, 2:641-649.
54. Min/+ mice. Oncol Rep 2010, 23:53-59.
55. Min/+ mouse model of intestinal tumorigenesis. Int J Oncol 2014, 45:861-868.
56. Baltgalvis K.A., Berger F.G., Peña M.M., Davis J.M., Carson J.A. Effect of exercise on biological pathways in ApcMin/+ mouse intestinal polyps. J Appl Physiol 2008, 104:1137-1143.
57. Mehl K.A., Davis J.M., Clements J.M., Berger F.G., Pena M.M., Carson J.A. Decreased intestinal polyp multiplicity is related to exercise mode and gender in ApcMin/+ mice. J Appl Physiol 2005, 98:2219-2225.
58. Zielinski M.R., Davis J.M., Fadel J.R., Youngstedt S.D. Influence of chronic moderate sleep restriction and exercise on inflammation and carcinogenesis in mice. Brain Behav Immun 2012, 26:672-679.
59. Min/+ mice. Drug Discov Ther 2014, 8:25-32.
60. Min/+ mice. Cancer Prev Res (Phila) 2010, 3:1187-1197.
61. Min/+ mouse polyps. Carcinogenesis 2011, 32:1333-1339.
62. Jacoby R.F., Seibert K., Cole C.E., Kelloff G., Lubet R.A. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 2000, 60:5040-5044.
63. Min/+ mouse. J Interferon Cytokine Res 2011, 31:2.
64. Min/+ mouse. Clin Cancer Res 1999, 5:855-863.
65. Min/+ mouse. Nutr Cancer 2011, 63:421-426.
66. Min/+ mice by silibinin. Cancer Res 2010, 70:2368-2378.
67. Min/+ mice. J Pharmacol Exp Ther 2014, 350:99-109.
68. Min/+ mice. Int J Cancer 2007, 121:506-513.
69. Hofseth L.J., Hussain S.P., Wogan G.N., Harris C.C. Nitric oxide in cancer and chemoprevention. Free Radic Biol Med 2003, 34:955-968.
70. Di Piazza M., Nowell C.S., Koch U., Durham A.D., Radtke F. Loss of cutaneous TSLP-dependent immune responses skews the balance of inflammation from tumor protective to tumor promoting. Cancer Cell 2012, 22:479-493.